Essential Partners’s PTC Therapeutics PTCT Stock Holding History

Essential Partners’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.9K	Sell	169 -2	-1%	-$146	0.01%	1156
2026 Q2	$13.9K	Sell	171 -2,198	-93%	-$159K	0.01%	1060
2026 Q1	$161K	Hold	2,369	–	–	0.05%	320
2025 Q4	$180K	Buy	2,369 +59	+3%	+$4.29K	0.06%	335
2025 Q3	$142K	Sell	2,310 -666	-22%	-$34.7K	0.05%	379
2025 Q2	$145K	Buy	+2,976	New	+$141K	0.06%	315

Other funds holding PTCT

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Essential Partners's PTCT Position: Q3 2026 in Review

Essential Partners reduced its PTC Therapeutics (PTCT) stake by 1.2% in Q3 2026, selling an estimated $146 and leaving 169 shares worth $10.9K. The position accounts for 0.01% of the portfolio, ranked #1156.

Essential Partners first reported a position in PTCT in Q2 2025 and has held it in 6 quarters since. The position peaked at $180K in Q4 2025. 50 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

Essential Partners held 169 shares of PTC Therapeutics worth $10.9K as of Q3 2026.
Essential Partners sold 2 PTC Therapeutics shares in Q3 2026, an estimated $146.
PTC Therapeutics made up 0.01% of Essential Partners's portfolio in Q3 2026, its #1156 holding.
Essential Partners first reported a position in PTC Therapeutics in Q2 2025 and has held it in 6 quarters since.
Essential Partners's PTC Therapeutics position peaked at $180K in Q4 2025.
50 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.